Polycyclic Amide Side Chain Variation for Topoisomerase Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticancer drugs targeting DNA topoisomerase have limited efficacy due to restricted structural variations in tricyclic compounds, particularly in amide side chains, which hinder optimal biological activity.
Innovation Solution
Development of novel cytotoxic polycyclic amide compounds with diverse amide side chains, synthesized through a specific route involving reactions with tricyclic carboxylic acids, hydroxylamine, and primary/secondary amines, to enhance biological activity against DNA topoisomerase.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If the standard amide side chain —CONH(CH2)2NMe2 is used in tricyclic compounds, then the synthesis is simple and inexpensive, but the biological activity is limited and cannot be significantly improved
Solution Approach 1:
The patent systematically varies the amide side chain structure by changing the substituent groups on the terminal nitrogen atom (R1 and R2 in —CONH(CH2)nNR1R2). Instead of using only methyl groups (—NMe2), the invention introduces diverse alkyl groups including ethyl, propyl, isopropyl, butyl, and their combinations, thereby changing the chemical parameters of the side chain to achieve significantly improved biological activity against DNA topoisomerase while maintaining reasonable synthetic accessibility
Solution Approach 2:
The invention focuses specifically on modifying the terminal amine group of the amide side chain while keeping the tricyclic core structure intact. This localized modification approach allows the main tricyclic structure to maintain its DNA-embedding capability while the modified terminal group enhances the interaction with topoisomerase, achieving improved biological activity without compromising the overall molecular framework
2Adaptability or versatility
If slightly different amide side chains such as —CONHCHMeCH2NMe2 or —CONHCHMeCONMe2 are used, then structural variation is introduced, but the biological activity reduces greatly by four orders of magnitude
Solution Approach 1:
The patent identifies that the key parameter for high biological activity is the terminal nitrogen substituent configuration. By systematically testing different alkyl groups (methyl, ethyl, propyl, isopropyl, butyl) at the terminal nitrogen position while maintaining the —CONH(CH2)n— linkage, the invention finds that bulky substitutions near the carbonyl group (like —CONHCHMeCH2NMe2) reduce activity, whereas terminal substitution with diverse alkyl groups (—CONH(CH2)2NR1R2 where R1,R2 are alkyl) enhances activity by four orders of magnitude
Solution Approach 2:
The invention introduces flexibility into the amide side chain by varying the chain length (n = 2-6) and the terminal substituent groups, allowing the molecule to adapt its conformation for optimal binding to DNA-topoisomerase complex. The flexible alkyl chains can adjust their spatial arrangement to maximize hydrophobic interactions and minimize steric hindrance, thereby maintaining high biological activity across different substituent combinations
Data Source
AI summary
A novel polycyclic amide compound, preparation process and use thereof are provided. The compound has cytotoxic biological activity, particularly for the treatment and/or prevention of cell proliferative diseases such as cancer. This compound is a compound represented by Formula I ora pharmaceutically acceptable salt, solvate, polymorph, enantiomer or racemic mixture, prodrug and N-oxide thereof, wherein, R, R1-R3 are independently selected from hydrogen, C1-5 alkyl, or C1-5 having a hydroxyl group or a halogen, and may be bonded to each other to form a ring, Z is an arbitrary substituent group, X1 and X2 may be carbon or nitrogen respectively, Q is oxygen or sulfur. Compared to the existing known polycyclic amide compounds, the novel polycyclic amide compound has more potent cytotoxicity and can be used for the treatment of diseases such as tumors, cancers, Alzheimer's disease, autoimmune diseases, cataracts, psychological disorders, depression and/or anxiety.